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Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56S267.1. One-sample t-statistic maps were calculated to describe task-
related activations, and ANOVA (SPM Full Factorial repeated meas-
urements within groups and independent between groups) was used
to identify group by session treatment interaction effects and to
compare groups and sessions. The main outcome measurement was
attenuation of the response evoked by knee painful stimulation in
the pain-processing brain system.
Results: Patients receiving CS showed a tendency to report reduced
subjective pain after treatment during patella pressure test (p¼0.077),
but no signiﬁcant group by session interaction was demonstrated. fMRI
of patella pain, showed a larger activation reduction in the CS group
than in placebo in a posterior mesencephalon region including the
periaqueductal gray (PAG). The entire PAG cluster (238 voxels) with
signiﬁcant interaction showed a pre>post-treatment difference at
p<0.05 (peak difference at x¼-4, y¼-40, z¼-16; t¼2.4, p¼0.01). In this
paired analysis, the CS group showed signiﬁcant activation reduction
in the primary somatosensory cortex (including the cortical repre-
sentation of the leg) and extending to the primary motor cortex and
posterior supplementary motor area. Group by session interaction
consistently revealed a tendency for this cortical change to be larger in
the CS than in placebo (peak interaction x¼2, y¼-6, z¼72; t¼2.96,
p¼0.002 and 43 voxels-subthreshold- with p<0.01) (Figure 1). No
effects of CS were detected using the knee interline pressure test.
Conclusions: The study succeeded in the primary objective as a sig-
niﬁcant effect was demonstrated showing attenuation of brain response
to painful pressure in key regions of the pain-processing network using
the patella test.
Despite knee medial interline is one of the most tenders points in
patients with knee osteoarthritis, pressure on this site may generate
pain from damage or sensitization in a variety of structures. The
pain generated by pressing down the patella surface, in contrast, is
probably less complex, and may be more selectively related to
sensitization processes in the bone and the junction between the
bone and cartilage as a result of erosion in the patella and femoral
cartilages. The observed positive treatment effect of CS is consistent
with the known CS action on cartilage protection due to chon-
drocyte regeneration. fMRI was able to objectify CS effects on brain
response to knee pressure painful stimulation, yielding further
support to the utility of fMRI to objectify treatment effects on OA
pain.
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Purpose: Peripheral and central sensitization can worsen knee
osteoarthritis (OA) pain. Focally administered onabotulinumtoxinA
(onabotA) has caused analgesia via disruption of peripheral release of
neurogenic inﬂammatory mediators (eg, glutamate, gene-related
peptide, substance P), which in turn reduces peripheral nociceptive
drive and peripheral sensitization, resulting in modiﬁed central pain
mediation. Inhibition of peripheral nociception in knee OA by intra-
articular (IA) injection of onabotA may be a new treatment modality.
This study aimed to evaluate the efﬁcacy of a single onabotA IA
injection in knee OA pain using traditional pain assessments (eg, daily
pain diary) and mechanistic, quantitative, experimental pain assess-
ment models to proﬁle peripheral and central actions. Safety data were
also collected.
Methods: Patients 40-75 y, with primary idiopathic knee OA and
Kellgren-Lawrence grade of I-III were enrolled in a 16-wk, double-
blind, placebo (PBO)-controlled study. Randomization was 1:1, strati-
ﬁed by 14-day baseline average daily worst pain (ADWP) score of 4.0-
9.0 (0-10 point numeric rating scale), to a single injection of ultra-
sound-guided IA onabotA (200 U) or PBO in the study knee. Primary
efﬁcacy endpoint was 14-day ADWP score change from baseline at wks
4, 8, and 12, jointly analyzed using repeated measures analysis of
covariance for between-group comparisons, adjusted for baseline
ADWP score; missing scores were imputed. 5 pain model evaluations
were conducted at baseline, day 1 pre-injection, and wks 4, 8, and 12:1) quantitative sensory testing of joint pain by pressure-pain threshold
(PPT) at 3 sites over the knee joint (3 cm medial, superior, or lateral to
edge of patella; 3-site average); 2) spreading sensitization testing by
PPT from the tibialis anterior muscle and ipsilateral extensor carpi
radialis longus muscle; 3) wind-up-like pain intensity (0-10 visual
analog scale) to experimental pressure pain stimuli using an automatic
pressure algometer to deliver 1 stimulus or 10 repeated stimuli (1 Hz)
over the tibialis anterior muscle and to the most painful site of the
study knee; 4) cuff algometry, which evaluated PPT via the mean of 3
measurements; 5) mapping of the total area of knee pain. Pain model
endpoints were analyzed using a Wilcoxon rank-sum test (calculated
by analysis of variance of ranked scores) without baseline covariate or
imputation.
Baseline Pain DETECT (PD-Q) scores were used post-hoc to classify
patients into pain subgroups of nociceptive (PD-Q12) or non-noci-
ceptive (13).
Results: Of 170 screened patients, 121 were randomized to onabotA
(n¼61) or PBO (n¼60); mean age 62.3 y, all Caucasian, and similar
numbers of men and women. No clinically relevant between-group
baseline differences were observed. The primary efﬁcacy analysis yiel-
ded no signiﬁcant difference between onabotA and PBO for the change
from baseline in ADWP score to the 3 time points (P¼0.70). Most pain
model tests showed no signiﬁcant difference at any time point. PPT in
the tibialis showed a trend toward improvement with onabotA at wks 4
(P¼0.08) and 8 (P¼0.07; Fig 1A). A similar trend was observed in wind-
up-like pain for the tibialis (wk 12, P¼0.13; Fig 1B). Posthoc analyses in
the 68 nociceptive pain patients showed signiﬁcant between-group
differences favoring onabotA for improved PPT over the tibialis at wks 4
(P¼0.03) and 8 (P¼0.02), with a trend at wk 12 (P¼0.13) and a trend for
the knee at wk 4 (P¼0.11; Fig 2A). A similar trend favoring onabotAwas
seen at wk 8 (P¼0.15) for wind-up-like pain at both tibialis and knee
(Fig 2B). The nociceptive subgroup also reported signiﬁcant pain relief
(P¼0.02; WOMAC pain score) favoring onabotA at wk 8, consistent with
a trend in daily worst pain intensity (P¼0.13).
Conclusion: This exploratory study found no signiﬁcant between-
group differences in the primary efﬁcacy endpoint. Pain model evalu-
ations indicated positive trends favoring onabotA. Post-hoc analyses in
the nociceptive subgroup showed that onabotA signiﬁcantly improved
outcomes in selected mechanistic pain models compared with PBO, in
parallel with reported pain relief. Mechanistic pain model evaluations
showed a larger trend of separation in both peripheral and spreading
pain (ie, central sensitization) than traditional clinical pain scores.
Disclosure: Funded by Allergan.39
RISK OF BIAS AND BRAND EXPLAIN THE OBSERVED INCONSISTENCY
IN TRIALS ON GLUCOSAMINE FOR OSTEOARTHRITIS:A META-
ANALYSIS OF PLACEBO-CONTROLLED TRIALS
P.R. Eriksen. The Parker Inst., Copenhagen, Denmark
Purpose: the aim of this study was to determine whether study
sponsor, chemical formulation, brand of glucosamine, and/or risk of bias
explain observed inconsistencies in trial ﬁndings of glucosamine’s
